Background: In 2016, England launched the largest nationwide diabetes mellitus prevention programme, the NHS Diabetes Prevention Programme (NHS DPP). This paper seeks to evaluate the long-term cost-effectiveness of this programme.
Methods: A Markov cohort state transition model was developed with a 35-year time horizon and yearly cycles to compare referral to the NHS DPP to usual care for individuals with non-diabetic hyperglycaemia. The modelled cohort of individuals mirrored the age profile of referrals received by the programme by April 2020. A health system perspective was taken, with costs in UK £ Sterling (price year 2020) and outcomes in terms of quality-adjusted life-years (QALYs). Probabilistic analysis with 10,000 Monte Carlo simulations was used. Several sensitivity analyses were conducted to explore the uncertainty surrounding the base case results, particularly varying the length of time for which the effectiveness of the programme was expected to last.
Results: In the base case, using only the observed effectiveness of the NHS DPP at 3 years, it was found that the programme is likely to dominate usual care, by generating on average 40.8 incremental QALYs whilst saving £135,755 in costs for a cohort of 1000. At a willingness to pay of £20,000 per QALY, 98.1% of simulations were on or under the willingness-to-pay threshold. Scaling this up to the number of referrals actually received by the NHS DPP prior to April 2020, cost savings of £71.4 million were estimated over the 35-year time horizon and an additional 21,472 QALYs generated. These results are robust to several sensitivity analyses.
Conclusion: The NHS DPP is likely to be cost-effective. Indeed, in the majority of the simulations, the NHS DPP was cost-saving and generated greater QALYs, dominating usual care. This research should serve as evidence to support the continued investment or recommissioning of diabetes prevention programmes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11252105 | PMC |
| http://dx.doi.org/10.1007/s41669-024-00487-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- Type 2 diabetes mellitus (T2DM) is a chronic condition marked by high blood sugar levels and insulin resistance, making effective management crucial to lowering health risks.
- A systematic review evaluated four primary treatments: SGLT2 inhibitors, DPP-4 inhibitors, metformin, and insulin, focusing on their effectiveness, safety, and long-term benefits based on recent randomized controlled trials.
- SGLT2 inhibitors showed additional cardiovascular and kidney benefits, while metformin remains a key first-line option. The review stresses the need for personalized treatment plans and suggests future research should explore direct comparisons and therapy sequences for better guidelines.
Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data.
Thorax
December 2024
Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK
Article Synopsis
- SGLT2 inhibitors and GLP-1 receptor agonists are diabetes treatments that may also lower the risk of pneumonia and severe sepsis in type 2 diabetes patients.
- A study using electronic medical records analyzed the effects of these drugs versus traditional glucose-lowering therapies and found significant reductions in pneumonia and sepsis risk.
- The findings suggest that both treatments could improve overall health outcomes beyond glucose control, but more research is needed to understand their full impact.
Long-Term Cardiovascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review.
Cureus
November 2024
General Medicine, General Hospital Lahore, Lahore, PAK.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a promising class of medications for type 2 diabetes (T2D) management. While their glucose-lowering effects are well-established, their long-term impact on cardiovascular outcomes remains a subject of ongoing research and debate. This systematic review aims to assess the long-term cardiovascular effects of GLP-1 RAs in adults with T2D compared to placebo, standard care, or other glucose-lowering medications.
View Article and Find Full Text PDFSevere early graft dysfunction post-heart transplantation: Two clinical trajectories and diastolic perfusion pressure as a predictor of mechanical circulatory support.
J Heart Lung Transplant
February 2025
Transplant Unit, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK.
Background: Severe early graft dysfunction (EGD) is defined by mechanical circulatory support (MCS) <24 hours of heart transplantation (HT). We classified severe EGD based on timing of post-HT MCS: ''Immediate'' intra-operative vs ''Delayed'' post-operative MCS (after admission into intensive care unit (ICU) from operating theater). We hypothesized that (1) risk factors and clinical course differ between ''Immediate'' and ''Delayed'' MCS; and (2) diastolic perfusion pressure (DPP=diastolic blood pressure-central venous pressure) and Norepinephrine equivalents (NE=sum of vasopressor doses), as measures of vasoplegia are related to ''Delayed'' MCS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!